ritanserin has been researched along with Hypoglycemia in 3 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Hypoglycemia: A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of serotonin in the insulin hypoglycemia (IH) stimulated secretion of prolactin (PRL), growth hormone (GH), adrenocorticotropin (ACTH) and cortisol (F) was studied in a group of 12 normal subjects during the control period after placebo and a consecutive six-day treatment with 20 mg ritanserin (RIT) per day." | 9.08 | Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans. ( Aganović, I; Giljević, Z; Halimi, S; Jelić, T; Korsić, M; Kozić, B; Plavsić, V; Suchanek, E; Tepavcević, D, 1995) |
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 7.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| "The role of serotonin in the insulin hypoglycemia (IH) stimulated secretion of prolactin (PRL), growth hormone (GH), adrenocorticotropin (ACTH) and cortisol (F) was studied in a group of 12 normal subjects during the control period after placebo and a consecutive six-day treatment with 20 mg ritanserin (RIT) per day." | 5.08 | Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans. ( Aganović, I; Giljević, Z; Halimi, S; Jelić, T; Korsić, M; Kozić, B; Plavsić, V; Suchanek, E; Tepavcević, D, 1995) |
| "In order to study the hypothesized impairment of the serotoninergic system in human obesity, an insulin tolerance test (ITT) was carried out on 12 obese normoprolactinemic women and on 6 normal-weight women before (A) and after (B) the administration of a serotoninergic drug, fenfluramine (60 mg twice a day per os for 7 days)." | 3.67 | Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system. ( Argenio, GF; Bernini, GP; Del Corso, C; Franchi, F; Luisi, M; Sgrò, M; Vivaldi, MS, 1989) |
| "Ritanserin is a new selective 5-HT2 blocker receptor agent." | 2.67 | Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration. ( Argenio, GF; Bernini, GP; Birindelli, R; Del Corso, C; Franchi, F; Luisi, M; Vivaldi, MS, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tepavcević, D | 1 |
| Giljević, Z | 1 |
| Aganović, I | 1 |
| Korsić, M | 1 |
| Halimi, S | 1 |
| Suchanek, E | 1 |
| Jelić, T | 1 |
| Kozić, B | 1 |
| Plavsić, V | 1 |
| Bernini, GP | 2 |
| Argenio, GF | 2 |
| Vivaldi, MS | 2 |
| Del Corso, C | 2 |
| Birindelli, R | 1 |
| Luisi, M | 2 |
| Franchi, F | 2 |
| Sgrò, M | 1 |
2 trials available for ritanserin and Hypoglycemia
| Article | Year |
|---|---|
Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans.
Topics: Adult; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Pituitary Hormones, Anterio | 1995 |
Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration.
Topics: Adult; Blood Glucose; Female; Fenfluramine; Growth Hormone; Humans; Hypoglycemia; Insulin; Middle Ag | 1990 |
1 other study available for ritanserin and Hypoglycemia
| Article | Year |
|---|---|
Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system.
Topics: Adolescent; Adult; Female; Fenfluramine; Humans; Hypoglycemia; Insulin; Middle Aged; Obesity; Piperi | 1989 |